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Background: Subjective tinnitus is a frequent, impairing condition, which may also cause 
neurotransmitter imbalance at the cochlea. Psychopharmacologic agents, although not being the 
first-line treatment for tinnitus, may modulate cochlear neurotransmission, thereby influencing 
the subjective tinnitus experience.
Method: A comprehensive review of MEDLINE literature (from January 1990–January 2010) 
was performed searching for: “tinnitus”, major classes of psychopharmacological agents, and 
psychiatric disorders. The most relevant clinical evidence is reported briefly along with a concise 
description of the main neurotransmitters purported to be involved in tinnitus, in order to provide 
the reader with a rational evaluation of tinnitus therapy with psychopharmacological agents. 
Results: Although strong methodological issues limit the reliability of the current results, a 
broad number of psychopharmacological agents have already been considered for tinnitus, both 
as candidate triggers or potential therapies.
Conclusions: Selected psychopharmacological drugs may play a role in the clinical management 
of this disorder. While the rational use of these agents for the treatment of tinnitus should not be 
overlooked, research should be undertaken on their neuromodulating actions at the cochlea.
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Introduction
Tinnitus, from the Latin word “tinnı¯ tus” meaning “ringing”1 is a perception of 
sound in the absence of external sounds (ICD-10 code, H93.1).2 This phenomenon 
can be divided into two broad groups: objective and subjective tinnitus. Objective 
tinnitus is provoked by sound generated in the body reaching the ear through con-
duction in body tissues, while subjective tinnitus is meaningless sounds that are not 
associated with any physical sound and it can be heard only by the suffering person. 
Although subjective tinnitus represents a far more prevalent condition compared 
to objective tinnitus,3 and thereby constitutes a more accessible phenomenon for 
investigators, current information available on its etiology is unsatisfactory. In 
fact, while a broad number of heterogeneous pathomechanisms and causes have 
been postulated (Table 1), no univocal consensus has been reached to date and its 
management is still a well debated issue. Furthermore, since there are many kinds 
of subjective tinnitus, the search for a (unique) cure is futile. As consequence, both 
researchers and clinicians have  progressively extended the portfolio of potential 
therapies (including nonfirst-choice  treatments such as psychopharmacological 
agents) especially for those patients whose tinnitus may be related to comorbid 
psychological stressors.4
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Since some forms of tinnitus may be exacerbated or 
moderated by psychopharmacological agents, the aim of the 
present paper is to provide the reader with an updated survey 
on their rational use in subjective tinnitus.
Data source and selection
A comprehensive review of English-written MED-
LINE results was retrieved using the following que-
ries:  “Tinnitus AND neurobiology”; “Tinnitus AND 
therapy”; “Tinnitus AND antidepressant”; “Tinnitus 
AND SSRI”; “Tinnitus AND venlafaxine”; “Tinnitus 
AND duloxetine”;  “Tinnitus AND bupropion”; “Tinnitus  AND 
tricyclic”; “Tinnitus AND benzodiazepine”; “Tinnitus AND 
lithium”; “Tinnitus AND antiepileptic”; “Tinnitus AND anxi-
ety”; “Tinnitus AND depression”; “Tinnitus AND bipolar 
disorder”; “Tinnitus AND schizophrenia”; “Tinnitus AND 
ADHD”; and “Tinnitus AND dementia”. Results were kept 
within a January 1990–January 2010 time limit. Finally, 
meta-analysis and randomized clinical trials (RCTs) data 
were prioritized when available.
Pathophysiology
The changes in the auditory nervous system, especially 
at the dorsal (DCN) and ventral cochlear nucleus (VCN) 
underpinning tinnitus are often represented by a reduc-
tion in the inhibitory rather than an excitatory input, 
resulting in a shift in the balance between inhibition and 
excitation.
Deprivation of input may cause neural plasticity to change 
the relationship between inhibition and excitation and pro-
tein synthesis5 and finally, impact on  neurotransmission— 
 especially at the DCN, the inferior colliculus (IC), together 
with the primary and secondary auditory cortices—eventually 
affecting the thalamic and dorsal cortex transmission, the 
amygdala, and other structures.6 The rerouting of information 
may cause structures of the central nervous system (CNS) that 
are not normally involved in processing auditory information 
to become activated by sound stimulation (ie, the abnormal 
involvement of the nonclassical–nonspecific/extralemniscal–
pathways). Yet to date, no univocal or exhaustive apprecia-
tion of tinnitus determining neural abnormalities has been 
Table 1 Main hypothesized pathomechanisms and causes of tinnitus
Main peripheral auditory system theories of subjective tinnitus
Spontaneous otoacoustic emissions Small acoustic signals perceived as tinnitus
edge theory increased spontaneous activity in the edge area
Discordant theory Discordant dysfunction of damaged outer hair cells and 
intact inner hair cells
Main central auditory system and somatosensory theories of subjective tinnitus
The dorsal cochlear nucleus Hyperactivity/plastic readjustment of DCN
Auditory plasticity theory enhanced neural activity due to cochlear damage
Crosstalk theory Ephaptic coupling between nerve fibers
Main causes of subjective tinnitus
Otologic problems and hearing loss Loud noise, presbycusis, Ménière’s disease, acoustic 
neuroma, external ear infection
Pharmacological causes Analgesics, antibiotics, chemotherapy and antiviral 
drugs, loop diuretics, antidepressants, psychedelic 
drugs (5-MeO-DeT, 5-Methoxy-diisopropyltryptamine, 
diisopropyltryptamine, harmaline, N,N-
dimethyltryptamine, psilocybin, salvinorin A)
Neurologic disorders Traumatic brain injury, meningitis, encephalitis, strokes, 
multiple sclerosis, chiari malformation, auditory nerve 
injury
Metabolic disorders Thyroid disorder, hyperlipidemia, vitamin B12 
deficiency, iron deficiency, anemia
Psychiatric disorders Anxious and depressive states
Other Tension myositis syndrome, fibromyalgia, head and neck 
muscle spasm, temporomandibular  joint disorders, 
thoracic outlet syndrome, lyme disease, hypnogogia, 
sleep paralysis, glomus tympanicum, herpes infections
Main causes of objective tinnitus
Pulsatile tinnitus: Altered blood flow or increased blood turbulence 
near the ear
Atherosclerosis, venous hum, carotid artery aneurysm, 
carotid artery dissection
Muscle contractions that cause clicks or crackling around the middle ear
Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
211
Tinnitus psychopharmacology
reached; with its  pathophysiological correlates still remaining 
a debated issue.
Among others, the following evidence and hypotheses 
have been postulated:7
Peripheral auditory system
Spontaneous otoacoustic emissions
Small acoustic signals presumed to be generated by the 
electromotile activity of the outer hair cells (OHCs) of the 
cochlea and propagated into the external auditory canal may 
be abnormally perceived as tinnitus.8
edge theory
Increased spontaneous activity in the edge area, which rep-
resents a transition from normal OHCs on the apical side of 
a lesion to OHCs toward the basal side that are missing or 
altered, may contribute to tinnitus perception.9
Discordant theory
The discordant dysfunction of damaged OHCs and intact 
inner hair cells (IHCs) may result in the disinhibition and 
increased spontaneous activity of neurons in the DCNs, 
that receive excitation from IHCs, but with no inputs from 
the damaged OHCs, therefore playing a role in tinnitus 
phenomenon.10
Central auditory system
The dorsal cochlear nucleus
Hyperactivity by disinhibition or plastic readjustments of the 
DCN, triggered for instance by OHC damage or a reduction 
in auditory nerve input have been supposed to concur in 
tinnitus genesis.11
Auditory plasticity theory
Damage to the cochlea enhances neural activity in the central 
auditory pathway, such as the IC and the temporal lobe of 
the auditory association cortex (similar to the phantom limb 
sensation in amputees).12
Crosstalk theory
The compression from blood vessels or a tumor on auditory 
nerve causes ephaptic coupling between nerve fibers, which 
may result in the phase-locking of spontaneous activity of 
groups of auditory neurons that may be perceived as sound.13
Somatosensory system
Abnormal DCN activity could also be influenced by the 
stimulation of the somatosensory system. Furthermore, pain 
signals from the cochlea carried by the cochlear C fibers may 
be interpreted by the CNS as tinnitus.14
Neurotransmitters
It has been postulated that numerous cochlear neurotransmit-
ters play a role in tinnitus sensation.
GABA
It is known that the number of gamma-aminobutyric acid 
(GABA) immunoreactive neurons in the auditory nuclei 
decreases with age;15 together with its concentration and 
release, the glutamatergic acid decarboxylase activity (the 
rate-limiting enzyme in the formation of GABA), GABA
B
 
receptor binding and the presynaptic GABA releasing ter-
minals availability.16 This trend has been postulated to be a 
higher risk of noise-induced hearing loss as an important 
tinnitus etiological factor, especially in older men17, and 
has prompted both researchers and clinicians to consider 
GABAergic modulators as a candidate therapy for tinnitus 
patients. Anxiolytic benzodiazepines (BDZ), as well as anti-
epileptic drugs that enhance GABA
A
 receptors (including 
those used as mood-stabilizers); or GABA
B
 agonists (eg, 
baclofen, a drug used for multiple sclerosis and proposed 
for morphine withdrawal syndrome18) have all been sug-
gested both for animal and human models of tinnitus.19,20 
Finally, while anxiety per se does not produce tinnitus, it may 
strongly exacerbate its perception, and may be modulated 
by GABAergic neurotransmission enhancers with the final 
result of tinnitus relief.
Serotonin
Serotonergic (5-HTergic) modulation (eg, by salicylate 
administration) has been reported to provoke tinnitus,21 
although human genetic studies on the regulatory region 
of the 5-HT transporter (5-HTTLPR) SLC6A4 gene failed 
to show any significant effect on the susceptibility to 
chronic tinnitus, thus indicating an indirect, rather than a 
direct, modulating role of 5-HT in tinnitus etiology and 
CNS-adaptive mechanisms.22 Modulation of 5-HT is a core 
mechanism of a very large number of routinely prescribed 
drugs including the selective serotonin reuptake inhibitor 
(SSRI) antidepressants, thus their putative role in increas-
ing the sensation of tinnitus should therefore be taken into 
account.23 Nonetheless, the biological theory of depres-
sion provides a rationale for the association of emotional 
distress and chronic tinnitus determined by the respective 
impact of dysfunctional neural reorganization on limbic and 
auditory structures,24 with a specific role of brain-derived 
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neurotrophic factor (BDNF) in promoting plasticity-in-
duced recovery, has been postulated in depressive states,25 
which could make some affective (or anxiety) disordered 
individuals more genetically prone26 or stress-vulnerable27 
for developing tinnitus.
Dopamine
Tinnitus perception takes place in prefrontal, primary 
temporal and temporoparietal associative areas, as well 
in the limbic system. Dopamine (DA) neurotransmission 
acts through prefrontal, primary temporal, temporoparietal 
associative areas and the limbic system. Tinnitus perception 
and DA-ergic pathway share the same cerebral structures, 
which control attention, stress, emotions, learning, memory 
and motivated behavior. Distress from tinnitus emanates 
from these same cerebral functions, and could therefore be 
potentially modulated by either DA-blockers (ie, typical and 
atypical antipsychotics) or DA-agonists (eg, buproprion, a 
norepinephrine/DA reuptake inhibitor, antidepressant and by 
many anti-Parkinson drugs such as levodopa,  bromocriptine, 
pramipexole and others).
Glutamate
N-methyl d-aspartate (NMDA) glutamate receptor is most 
likely involved in tinnitus, as it is involved in many forms 
of central neuropathic pain.28 Specifically, it has been 
shown that acetylsalicylic acid activates cochlear NMDA 
receptors29 and that the use of NMDA-antagonists at the 
round window abolishes tinnitus,29 while NMDA receptor 
agonists may induce tinnitus-like behaviors.30 Memantine, 
used to treat neuropathic pain and mild to moderate forms 
of Alzheimer’s disease,31 blocks NMDA transmission in hair 
cells (the same as salicylate acts upon)32 also modulating 
the cholinergic transmission. Acamprosate, a drug acting 
as both a NDMA-blocker and GABA-enhancer is used for 
alcohol withdrawal maintenance,33 recently proposed as an 
(augmentation) strategy to improve cognitive depressive 
symptoms,34 has recently been trialed for the management 
tinnitus with some success.35 Salicylate amplifies cochlear 
NMDA-mediated responses but has little or no effect on 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic (AMPA) 
glutamate receptor and  glutamatergic kainite- mediated 
responses.36 AMPA receptors (AMPAR) are both glutamate 
receptors and cation channels that are integral to plasticity 
and synaptic transmission at many postsynaptic membranes. 
AMPA receptors mediate the excitotoxic effect of excessive 
noise trauma, leading to  excessive amounts of glutamate in 
the synaptic cleft that results in neurite loss,37 and are also able 
to upregulate themselves through plastic changes.38 Applica-
tion of NMDA antagonists onto the round window membrane 
abolishes tinnitus, even in animals receiving treatment with 
the 5-HT
2C
 anxiogenic agent 1-(-3-chlorophenyl) piperazine 
(mCPP),39 suggesting NMDA blocking, even for depressed 
or chronically anxious tinnitus patients.40
ion channel and others
The inner cells of the cochlea have only the L-type of 
calcium (Ca2+) channels, that are involved in the regula-
tion of in situ glutamate release and are blocked by salicy-
late.41 In the IC, the current through the L-type channels, 
although unable to directly trigger the neurotransmitter 
release, contributes to GABAergic transmission by acti-
vating the second messenger system and/or by increas-
ing the intracellular Ca2+ connection;42 while salicylate 
also blocks the outward and delayed rectifier potassium 
(K+) channels in rat IC, hence decreasing the GABAergic 
transmission.43
Glycine receptors (whose number significantly decreases 
with age in DCN) along with acetylcholine muscarinic and 
nicotinic receptors (whose number also decreases with age in 
the VCN and IC) antagonism has also been investigated for 
their implication in the genesis of tinnitus44,45 and may lead to 
new pharmacological strategies (such as with varenicline, a 
smoking-cessation drug and often prescribed to psychiatric 
patients46) in the treatment of tinnitus.
Psychopharmacological treatment
Many drugs, including psychopharmacological agents, are 
routinely employed in the treatment of tinnitus (Table  2). 
Such drugs could be prescribed as both a potential therapy for 
tinnitus, or just to patients with psychopathological problems 
who may also present with tinnitus, or to patients who may 
develop tinnitus (possibly as iatrogenic phenomenon).
Antidepressants
Baldo and colleagues performed a meta-analysis in 2006 on 
tricyclic antidepressants (TCAs) and SSRIs, which ques-
tioned substantially their efficacy in the treatment of tin-
nitus, although most evidence may have been invalidated by 
methodological bias or the reliance on single case reports.47 In 
2007, an analysis of four RCTs by Robinson found that higher 
doses of SSRIs and TCAs appear to work for tinnitus patients 
who also exhibit depression and anxiety48 or insomnia,49 both 
of which are frequent comorbidities among chronic otolar-
yngic patients.50 What appears to be irreversible disability 
of otologic origin may, in part, be a reversible disability of 
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Table 2 Main pharmacological agents for subjective tinnitus
Drugs Rationale Evidence
Antidepressants
TCAs NA- and 5HT-ergic transmission  
modulation, anticholinergic action,  
BDNF synthesis enhancement
Nortriptyline Superior to placebo (rTC) (higher  
doses of TCAs and SSris appear to work  
for tinnitus patients who also exhibit  
depression and anxiety or insomnia)
Amitriptyline Some success (case reports and a single  
blind study). Low doses sometimes 
related to tinnitus onset 
Trimipramine Less effective than placebo (rTC)
Clomipramine High doses associated with tinnitus onset
SSris 5HT-ergic transmission modulation,  
BDNF synthesis enhancement
Paroxetine No significant improvement for 
nondepressed patients (rTC)
Sertraline More effective than placebo for severe 
refractory tinnitus cases (rTC)
Fluoxetine worsening of most of the tinnitus cases
SNris NA- and 5HT-ergic transmission modulation, 
BDNF synthesis enhancement 
Duloxetine withdrawal has been seldom associated  
with tinnitus
venlafaxine Some success (case reports); withdrawal  
has been seldom associated with tinnitus 
NDris NA- and DA-ergic transmission modulation, 
BDNF synthesis enhancement 
Bupropion Limited-sample reports indicated its 
potential induction of tinnitus
Heterocyclics Mianserin Lack of evidence
Trazodone Lack of evidence
Sedative-hypnotics
Benzodiazepines GABA-A-ergic transmission modulation 
(alprazolam, clonazepam, midazolam: short  
half/average-life and pro 5-HT-ergic features)
Alprazolam Superior to placebo in the treatment  
of severe disabling tinnitus of 
predominantly cochlear origin (effective 
especially for those patients presenting 
high levels of co-morbid anxiety)
Clonazepam Superior to placebo (effective also  
for pulsatile tinnitus when associated  
with beta-blocker agents)
Midazolam Superior to placebo
GABA-B agonists Muscle relaxing and antispastic action Baclofen effective for pulsatile tinnitus
Mood stabilizers
Antiepileptics GABA-ergic transmission enhancement,  
GABA transaminase inhibition, alpha (2) delta  
calcium channel antagonism, others (histone  
deacetylases role, GSK-3 remodeling  
and synapsin i clustering)
Carbamazepine Some success in case reports and trials  
(limited sampled reports indicated its 
potential induction of objective tinnitus)
Gabapentin effective in reducing subjective or 
objective tinnitus, especially in individuals 
with associated acoustic trauma (rTC)
Lamotrigine ineffective (rTC)
valproate effective in a single case study (while  
another single-case evidence reported its 
potential role in inducing tinnitus)
vigabatrin Animal studies only
Pregabalin No systematic evidence
Lithium inhibitory effect on the phosphoinositide  
cascade, proserotonergic at higher  
doses? Others 
Not systematically assessed for tinnitus
Glutamatergic compounds
Acamprosate NDMA receptor blockade and  
GABA-ergic transmission enhancing
Superior than placebo in a double-blind study (potentially 
effective even for depressed or chronically anxious tinnitus 
patients)
Memantine Hair cells NMDA transmission blockade  
and cholinergic modulation
Not yet investigated in humans for tinnitus treatment
(Continued)
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Table 2 (Continued)
Drugs Rationale Evidence
Antipsychotics
Typical Auditolimbic D2 DA-ergic modulation Cases of schizophrenic patients treated with antipsychotics for 
tinnitus-like sensations
Atypical Dose-depending D2 receptor antagonism 
(postsynaptic D2-blockade at high doses  
and presynaptic auto-inhibitory D2-blockade  
at low doses with DA release instead  
of reduction), D2 partial agonism, others
Sulpiride  
(low doses)  
+ hydroxyzine  
or melatonin
Superior to placebo in a single blind 
placebo-controlled study and in a rTC
Lidocain L-type CA++ channels blockade, indirectly 
contributing to glutamatergic, GABA-ergic  
and cholinergic transmission modulation
Partially effective
Melatonin Pineal neurohormone with melatonergic  
agonism and anti-DA-ergic actions
Partially effective, especially in patients with sleep disturbance
Botulinum toxin inhibition of acetylcholine release  
at the neuromuscular junction
Partially effective in somatic tinnitus
Zinc, antioxidants, minerals, 
vitamins, ginko biloba  
and other herbal remedies
Different mechanisms of action Alternate results or ineffective
Unassessed potential targets
Agomelatine MT1/MT2 melatonergic agonism  
and 5-HT2C-ergic antagonism
No evidence to date
varenicline Nicotinic acetylcholine receptor  
partial agonism 
No evidence to date
Abbreviations: DA, dopamine; TCA, tricyclic antidepressants; CA, calcium; GABA gamma-aminobutyric acid; SSris, selective serotonin reuptake inhibitors; SNris, serotonin 
norepinephrine reuptake inhibitors; NDris, norepinephrine and dopamine reuptake inhibitors; NDMA, N-methyl D-aspartate; rTC, relaxation training control; BDNF, brain-
derived neurotropic factor; NA, noradrenaline; GSK-3, glycogen synthase kinase-3; MT, metallothionen.
psychiatric origin when treated51,52 with drugs proven to be 
effective  antidepressants such as nortriptyline.53
Some TCAs have proven not to be effective for tinnitus,54,55 or 
were even less effective than placebo56 (or possibly being associ-
ated with tinnitus onset with high doses of clomipramine).57
A possible dose effect may exist as lower doses have 
sometimes been related to tinnitus onset,58,59 even when the 
same agents were reported as being effective60 (as in non-
TCA heterocyclic antidepressants such as trazodone61 and 
mianserin).62
Sertraline was found to be more effective than placebo 
for severe refractory tinnitus cases63 although its discon-
tinuation was associated with tinnitus onset.64 Other SSRIs 
(eg, paroxetine) provided no significant improvement for 
nondepressed patients65 or even exacerbated tinnitus (eg, 
fluoxetine).66
While newer antidepressants have not been investigated 
as thoroughly as SSRIs and TCAs, little data on their role 
in the treatment of tinnitus has been reported and which has 
sometimes led to inhomogeneous evidence.
Serotonin norepinephrine reuptake inhibitors (SNRIs) 
withdrawal has seldom been associated with tinnitus (both for 
venlafaxine67,68 and duloxetine69), while the norepinephrine 
dopamine reuptake inhibitor (NDRI) bupropion may mimic 
a transient ischemic attack that may induce tinnitus,70,71 that 
is most likely due to DA-ergic enhancment.
Antipsychotics
Although pharmacological treatment is well-established for 
tinnitus in clinical practice systematic, rigorous literature 
evidence on antipsychotics is lacking, especially with regard 
to recently introduced atypical compounds.
Also, it is sometimes difficult to separate tinnitus from 
psychotic symptoms, thus increasing the cases of schizo-
phrenic patients who may receive antipsychotics for tinnitus-
like sensations or hallucinations.72
To date the most accurately investigated antipsychotic 
medication for tinnitus is sulpiride.
A 2007 prospective, randomized, single blinded, 
placebo-controlled study by Lopez-Gonzalez on sulpiride 
plus hydroxyzine (an antihistamine derivate and subcortical 
sedative attenuating the limbic system) indicated the efficacy 
of the antipsychotic drug in reducing the sensation of tin-
nitus, possibly mediated by the auditolimbic D
2
 DA-ergic 
modulation.73 An RCT investigation from the same group 
also reported the efficacy of sulpiride in association with 
melatonin (a pineal hormone with anti-DA-ergic actions) in 
attenuating tinnitus sensation.74 Remarkably, both studies used 
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low doses of sulpiride (up to 50 mg/8 hours) and this should 
be taken into account when using (atypical) antipsychotics, 
since the presynaptic autoinhibitory D
2
-blockade should lead 
to DA release instead of reduction (as evidenced by high dose-
mediated postsynaptic D
2
 heteroreceptors blockade).
The melatonergic role has also been considered for 
associations with antipsychotics other than sulpiride,75 and 
is worthy of further investigation, even for other classes of 
drugs (ie, the newly introduced antidepressant agomelatine, 
acting as metallothionen-1(MT1)/MT2 melatonergic agonist 
and 5-HT
2C
-ergic antagonist).76
Mood stabilizers
Many antiepileptics used as mood stabilizers have been 
considered for the treatment of tinnitus, although almost all 
available evidence does not come from systematic investiga-
tions and therefore do not lead to an univocal consensus.
Among others, carbamazepine has been proposed both as 
stand-alone treatment for subjective tinnitus77 or with lidocaine,78 
salicylate,79 or steroid80 augmentation/switch option, while lim-
ited-sampled reports indicate its potential induction of objective 
tinnitus (by auditory nerve vascular compression).81,82
Valproate, an another popular antiepileptic/mood-
stabilizer, has also been investigated as a candidate for tin-
nitus therapy.83,84 However a singlecase has been reported 
suggesting its potential role in inducing tinnitus (eventually 
by magnesium metabolism impairment),85,86 with tinnitus 
eventually being misinterpreted as psychotic symptom.87 
The only RCT evidence for lamotrigine concluded it to be 
ineffective for tinnitus.88
To date, gabapentin is the most thoroughly investigated 
antiepileptic drug for tinnitus. A placebo-controlled trial by 
Bauer and colleagues reported its effectiveness in reducing 
subjective or objective tinnitus, especially in individuals with 
associated acoustic trauma.89 However, more recent, placebo-
controlled studies using high doses of gabapentin (1800 
mg/day and 900–3600 mg/day respectively) have disproved 
its efficacy versus placebo.90–92 Remarkably, no systematic 
studies on the use of pregabalin (a gabapentin-related GABA-
modulator plus alpha (2) delta calcium channel antagonism) 
have been reported to date. However, evidence from the 
literature on tinnitus relief by CA2+ antagonists93 suggests 
that an investigation into applicability in the treatment of 
tinnitus is warranted.41
Lithium, a proven nonantiepileptic mood-stabilizer, 
has not been systematically assessed for its suitability for 
the treatment of tinnitus, although its inhibitory effect 
on the phosphoinositide cascade, maximized in case of 
over-the-counter assumption, may lead to vasodilatory shock 
as well as to hearing deficiency.94
Finally, while GABA transaminase inhibition is consid-
ered a basic antiepileptic feature, antimanic actions seem 
to be independent of it, with recent acquisition focusing on 
the role of histone deacetylases95 and the glycogen synthase 
kiase-3 remodeling and synapsin I clustering.96 This con-
sideration contributes to explain why the mood stabilizers 
class includes so much different compounds, whereas the 
GABA modulation is just part of the therapeutic portfolio, 
thus making particularly difficult to investigate a single action 
hypothesized to modulate tinnitus perception.
Sedative-hypnotics
Benzodiazepines (BDZs) and other sedative–hypnotics agents 
are among the most prescribed drugs worldwide and the piv-
otal role of BDZ receptor distribution in severe, intractable 
tinnitus has been studied by Daftary and colleagues.97 It is 
therefore unsurprising that BDZ GABA-A-ergic modulation 
has repeatedly been considered for treating severe disabling 
tinnitus of predominantly cochlear origin.98
Although systematic investigations are lacking, the 
majority of evidence suggests their potential role in tin-
nitus management, especially for those patients presenting 
with high levels of comorbid anxiety. Placebo-controlled 
trials for alprazolam,99 midazolam,100 and clonazepam101 
have produced the most promising results (remarkably, 
these drugs share the short half/average-life and the pro-5-
HT-ergic features). Clonazepam has also been reported as 
being effective for the treatment of pulsatile tinnitus when 
associated with beta-blocker agents,102 although less effec-
tive than baclofen (a muscle relaxer and an antispasmodic 
GABA-B-agonist agent).103 While no systematic trials 
have been conducted on the long half-life BDZs, it has 
been observed that the chance of protracted tinnitus due to 
abrupt discontinuation of  diazepam (30 mg/day long-term 
treatment)104 or oxazepam105 is most likely due to a receptor 
upregulation phenomena.
Conclusions
Tinnitus pharmacological therapies include a wide range of 
proposed medicaments. Among others, zinc,106 melatonin,75 
lidocaine,107 botulinum toxin,108 antioxidants minerals, 
 vitamins, ginkgo biloba, and other herbal remedies,109 have 
been considered in the treatment of tinnitus.
Indeed, psychological (eg, cognitive behavioral therapy) 
and retraining approaches have been suggested repeatedly as 
preferred integrative or stand-alone treatments.110 However, 
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psychopharmacological agents are often considered choices 
as well, although it is difficult to assess their efficacy.
In fact, major limits influence the validity of available lit-
erature evidence. Few studies follow RCT standards and most 
reports rely on small-sized samples or are just  single-case 
reports, with the literature evidence considered by this review 
relying on MEDLINE.
Also clinical diagnosis of tinnitus are extremely 
 heterogeneous and could be “influenced” by concomitant 
comorbidities/therapies, especially in case of anxious and 
depressed patients. These considerations inevitably limit the 
comprehension of the underpinning neurobiological sub-
strates of tinnitus, further reducing the chance of developing 
selective pharmacological agents.
Nonetheless, while psychopharmacological agents include 
a heterogeneous, broad number of compounds, the rational 
acknowledgment of studies in the current literature and 
hypothesized biological causes should be considered manda-
tory in order to avoid iatrogenic phenomena or to effectively 
consider the psychopharmacological treatment strategy.
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